Darovasertib/Crizotinib Combo Achieves Promising Responses in Pretreated Metastatic Uveal Melanoma
Source: Cancer Network, January 2022
Patients with heavily pretreated metastatic uveal melanoma appeared to benefit from treatment with a synthetic lethal combination of darovasertib and crizotinib.
Treatment with the synthetic lethal combination of darovasertib (IDE-196) and crizotinib (Xalkori) resulted in promising responses in a population of patients with heavily pre-treated metastatic uveal melanoma, according to a press release of a clinical update on a phase 1/2 trial.
All of the 16 evaluable patients on the trial experienced demonstratable tumor shrinkage, translating to a disease control rate of 100%. Additionally, investigators reported an overall response rate of 31%, with 4 patients achieving a confirmed partial response (PR). Thus far, no patients have withdrawn from treatment prior to the second scan. Among those with more than 2 baseline scans, 46% experienced tumor shrinkage of more than 30%; this included an unconfirmed PR that requires next tumor assessment.